FBXO3

Across TCGA pan-cancer cohorts, FBXO3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FBXO3 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FBXO3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FBXO3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

PDAC, UCEC, and GBM are the cancer types where FBXO3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.203	0.678	.021	16	view →
UCEC	DFS	Quartile	III,IV	0.238	1.000	.006	12	view →
GBM	OS	Median	All	0.274	0.519	.030	6	view →
LUAD	OS	Median	II,III,IV	0.893	0.457	.029	3	view →
CCRCC	DFS	Quartile	II,III,IV	0.933	0.750	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FBXO3–PDAC (DFS)

Open the PDAC breakdown →